The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Progress Toward Identification of Protease Activity Involved in Proteolysis of Apolipoprotein E in Human Brain
Abstract
Apolipoprotein E (apoE) genotype is the single most important genetic risk factor for the most common (sporadic) form of Alzheimer's disease (AD). Increasing evidence supports the hypothesis that the presence of the E4 isoform of this cholesterol-binding protein contributes directly to disease risk, age of onset, and severity of the neuropathology. For example, studies in transgenic mice demonstrate that apoE is necessary for the formation of plaques with neuritic pathology. The precise mechanism by which apoE contributes to the disease remains unknown. However, several lines of investigation from a number of laboratories now point to a role for proteolytic fragments of apoE in the formation of both plaques and tangles, the two pathological hallmarks of the disease. In particular, the C-terminal portion of apoE has been implicated in binding to amyloid and is localized to plaques. The N-terminal domain, on the other hand, is neurotoxic in culture and has been localized to, and implicated in the formation of, neurofibrillary tangles. These results suggest that inhibition of apoE proteolysis is a potential therapeutic strategy for AD. Using human brain homogenates, we have determined that proteolysis of apoE is greatest at acidic pH and can be inhibited by compounds targeting aspartic proteases. The feasibility of screening candidate inhibitors is supported by both ELISA and immunoblotting methods. Future studies will use a combination of in vitro and in vivo assays to test the…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has also been recognized that co-deposition of apoE in Aβ plaques promotes focal neurodegeneration in humans and in AD Tg mice [22,29,35].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [35]
Citations
Cites
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
Senile dementia of the Alzheimer type
Terry, R. D., & Katzman, R. (1983) · Annals of Neurology · doi:10.1002/ana.410140502 · Cited by 839
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Boyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., & Taylor, J. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112130 · Cited by 829
Differential Effects of Apolipoproteins E3 and E4 on Neuronal Growth in Vitro
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., & Pitas, R. E. (1994) · Science · doi:10.1126/science.8171342 · Cited by 795
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Apolipoprotein E in animal models of CNS injury and in alzheimer's disease
Poirier, J. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90156-2 · Cited by 637
Cited by
Sorted by citations
Apolipoprotein E: From lipid transport to neurobiology
Hauser, P. S., Narayanaswami, V., & Ryan, R. O. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.09.001 · Cited by 320
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation
Lanfranco, M. F., Sepulveda, J., Kopetsky, G., & Rebeck, G. W. (2021) · Glia · doi:10.1002/glia.23974 · Cited by 164
Huynh, T.-P. V., Wang, C., Tran, A. C., Tabor, G. T., Mahan, T. E., Francis, C. M., Finn, M. B., Spellman, R., Manis, M., Tanzi, R. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0337-1 · Cited by 139
Cholesterol in Alzheimers Disease: Unresolved Questions
Stefani, M., & Liguri, G. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313899 · Cited by 136
Cathepsin D-mediated proteolysis of apolipoprotein E: Possible role in Alzheimer’s disease
Zhou, W., Scott, S. A., Shelton, S. B., & Crutcher, K. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.019 · Cited by 84
Self-citationPane, K., Sgambati, V., Zanfardino, A., Smaldone, G., Cafaro, V., Angrisano, T., Pedone, E. M., Gaetano, S. D., Capasso, D., Haney, E. F., et al. (2016) · FEBS Journal · doi:10.1111/febs.13725 · Cited by 74
Neuronal nicotinic acetylcholine receptor–cholesterol crosstalk in Alzheimer's disease
Barrantes, F. J., Borroni, V., & Vallés, S. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.11.036 · Cited by 66
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57
Isoform-specific proteolysis of apolipoprotein-E in the brain
Elliott, D. A., Tsoi, K., Holinkova, S., Chan, S. L., Kim, W. S., Halliday, G. M., Rye, K., & Garner, B. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.006 · Cited by 59
Rohn, T. T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714908 · Cited by 58
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Rohn, T. T., Catlin, L. W., Coonse, K., & Habig, J. W. (2012) · Brain Research · doi:10.1016/j.brainres.2012.08.003 · Cited by 44
Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease
Tamboli, I. Y., Heo, D., & Rebeck, G. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093120 · Cited by 35
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
A 13 kDa carboxy‐terminal fragment of ApoE stabilizes Abeta hexamers
Wellnitz, S., Friedlein, A., Bonanni, C., Anquez, V., Goepfert, F., Loetscher, H., Adessi, C., & Czech, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03295.x · Cited by 26
Muñoz, S. S., Li, H., Ruberu, K. R., Chu, Q., Saghatelian, A., Ooi, L., & Garner, B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001278 · Cited by 24
(2017) · PubMed Central · Cited by 20
Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way
Xu, H. J., Gupta, V. B., Martins, I. J., Martins, R. N., Fowler, C. J., Bush, A. I., Finkelstein, D. I., & Adlard, P. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.016 · Cited by 20
Host Defence Cryptides from Human Apolipoproteins: Applications in Medicinal Chemistry
Gaglione, R., Pizzo, E., Notomista, E., de la Fuente‐Núñez, C., & Arciello, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200427091454 · Cited by 18
Wang, M., & Turko, I. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061498 · Cited by 16
Proteomic Identification of Novel Plasma Kallikrein Substrates in the Astrocyte Secretome
Liu, J., Gao, B., & Feener, E. P. (2010) · Translational Stroke Research · doi:10.1007/s12975-010-0039-z · Cited by 15
Frisardi, V. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111568 · Cited by 7
Suenaga, M., Furuta, A., Wakabayashi, K., Saibara, T., & Matsunaga, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.04.028 · Cited by 4
Effec ts of hyperoxia in alzheimers transgenic mice
Cox, A. (2005) · Digital Commons - University of South Florida (University of South Florida)
The Proteolysis of Apolipoprotein E in Alzheimer's Disease
Love, J. E. (2016) · ScholarWorks (Boise State University)
AXL receptor tyrosine kinase regulates Apolipoprotein E expression
Zhao, W. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0372324
Metadata
- Authors
- Marques, M. A., Owens, P. A., & Crutcher, K. A.
- Affiliations
- University of Cincinnati (US)
- Corresponding author
- Crutcher, Keith A.
- ORCID
- Crutcher, Keith A.
- Venue
- Journal of Molecular Neuroscience
- Published
- 2004
- Volume
- 24
- Issue
- 1
- Pages
- 073-080
- ISSN
- 0895-8696 (ISSN-L)
- OpenAlex
- W2021255192
- Cited by
- 29
- References
- 74
- Citations by year
- 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Molecular Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- apolipoprotein E, Alzheimer's disease, aspartic protease, protease inhibitors, APOE ε4, amyloid plaques, neurofibrillary tangles, human brain, inhibitor screening, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Peptide Fragments, Peptide Hydrolases, Neurofibrillary Tangles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
